Przypadki kliniczne w nadciśnieniu tętniczym i łagodnym rozroście gruczołu krokowego Opis serii przypadków
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2014
Słowa kluczowe:
łagodny rozrost stercza, nadciśnienie tętnicze, α1-adrenolityki
##plugins.themes.bootstrap3.article.main##
Abstrakt
Przedstawiono 3 przypadki pacjentów z nadciśnieniem tętniczym, towarzyszącym łagodnym rozrostem gruczołu krokowego i innymi problemami klinicznymi, np. chorobą niedokrwienną serca, zaburzeniami erekcji czy otyłością, w których uroselektywny α1-adrenolityk, tamsulosyna w formie o przedłużonym działaniu, znalazł zastosowanie kliniczne.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kostka-Jeziorny , K., & Tykarski , A. (2014). Przypadki kliniczne w nadciśnieniu tętniczym i łagodnym rozroście gruczołu krokowego . Medycyna Faktów , 7(4(25), 12-23. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2332
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Auerbach S.M., Gittelman M., Mazzu A.: Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004; 64: 998-1004.
2. Shabsigh R., Perelman M.A., Lockhart D.C. et al.: Health issues of men: Prevalence and correlates of erectile dysfunction. J. Urol. 2005; 174: 662-667.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. JAMA 2000; 283: 1967-1975.
4. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Nadciśnienie Tętnicze 2011; 15: 55-82.
5. Dusing R.: Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press. 2003; 12(supl. 2): 29-34.
6. Rosen R., Altwein J., Boyle P. et al.: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. 2003; 44: 637-649.
7. van Moorselaar R.J., Hartung R., Emberton M. et al.; for the ALFONE Study Group: Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int. 2005; 95: 603-608.
8. Kloner R.A., Jackson G., Emmick J.T. et al.: Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J. Urol. 2004; 172(5 Pt 1): 1935-1940.
9. Guillaume M., Lonsdale F., Darstein C. et al.: Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil and the α-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. Pharmacol. J. Clin. 2007; 47(10): 1303-1310.
10. Dusing R.: Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press. 2003; 12(supl. 2): 29-34.
11. Grimm R.H. Jr, Grandis G.A., Prineas R.J. et al.: Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Hypertension 1997; 29: 8-14.
12. Kostis J.B., Jackson G., Rosen R. et al.: Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am. J. Cardiol. 2005; 96: 313-321.
13. Oliver S.E., Barrass B., Gunnell D.J. et al.: Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle- aged men without evidence of prostate cancer. Int. J. Cancer 2004; 108: 887-892.
14. Dahle S.E., Chokkalingam A.P., Gao Y.T. et al.: Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J. Urol. 2002; 168: 599-604.
15. Hammarsten J., Högstedt B., Holthuis N. et al.: Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998; 1: 157-162.
16. Hammarsten J., Högstedt B.: Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8: 29-36.
17. Haffner S.M.: Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int. J. Obes. Relat. Metab. Disord. 2000; 24(Supl. 2): S56-S58.
18. Gann P.H., Hennekens C.H., Longcope C et al.: A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995; 26: 40-49.
2. Shabsigh R., Perelman M.A., Lockhart D.C. et al.: Health issues of men: Prevalence and correlates of erectile dysfunction. J. Urol. 2005; 174: 662-667.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. JAMA 2000; 283: 1967-1975.
4. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Nadciśnienie Tętnicze 2011; 15: 55-82.
5. Dusing R.: Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press. 2003; 12(supl. 2): 29-34.
6. Rosen R., Altwein J., Boyle P. et al.: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. 2003; 44: 637-649.
7. van Moorselaar R.J., Hartung R., Emberton M. et al.; for the ALFONE Study Group: Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int. 2005; 95: 603-608.
8. Kloner R.A., Jackson G., Emmick J.T. et al.: Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J. Urol. 2004; 172(5 Pt 1): 1935-1940.
9. Guillaume M., Lonsdale F., Darstein C. et al.: Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil and the α-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. Pharmacol. J. Clin. 2007; 47(10): 1303-1310.
10. Dusing R.: Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press. 2003; 12(supl. 2): 29-34.
11. Grimm R.H. Jr, Grandis G.A., Prineas R.J. et al.: Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Hypertension 1997; 29: 8-14.
12. Kostis J.B., Jackson G., Rosen R. et al.: Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am. J. Cardiol. 2005; 96: 313-321.
13. Oliver S.E., Barrass B., Gunnell D.J. et al.: Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle- aged men without evidence of prostate cancer. Int. J. Cancer 2004; 108: 887-892.
14. Dahle S.E., Chokkalingam A.P., Gao Y.T. et al.: Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J. Urol. 2002; 168: 599-604.
15. Hammarsten J., Högstedt B., Holthuis N. et al.: Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998; 1: 157-162.
16. Hammarsten J., Högstedt B.: Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8: 29-36.
17. Haffner S.M.: Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int. J. Obes. Relat. Metab. Disord. 2000; 24(Supl. 2): S56-S58.
18. Gann P.H., Hennekens C.H., Longcope C et al.: A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995; 26: 40-49.